Randomized Controlled Trial
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Lancet. 2019 Apr 27; 393 (10182): 1699-1707.
Randomized Controlled Trial
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Lancet. 2017 Jun 10; 389 (10086): 2304-2316.
Randomized Controlled Trial
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
J. Intern. Med. 2019 Jun 1; 285 (6): 653-669.